133 related articles for article (PubMed ID: 28486999)
1. GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.
Scope A; Essat M; Pandor A; Rafia R; Ward SE; Wyld L; Cross S; Woods HB
Int J Technol Assess Health Care; 2017 Jan; 33(1):32-45. PubMed ID: 28486999
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
5. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
Blok EJ; Bastiaannet E; van den Hout WB; Liefers GJ; Smit VTHBM; Kroep JR; van de Velde CJH
Cancer Treat Rev; 2018 Jan; 62():74-90. PubMed ID: 29175678
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
8. Impact of gene expression profiling tests on breast cancer outcomes.
Marchionni L; Wilson RF; Marinopoulos SS; Wolff AC; Parmigiani G; Bass EB; Goodman SN
Evid Rep Technol Assess (Full Rep); 2007 Dec; (160):1-105. PubMed ID: 18457476
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
10. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
Hornberger J; Alvarado MD; Rebecca C; Gutierrez HR; Yu TM; Gradishar WJ
J Natl Cancer Inst; 2012 Jul; 104(14):1068-79. PubMed ID: 22767204
[TBL] [Abstract][Full Text] [Related]
11. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Goldstein DA; Mayer C; Shochat T; Reinhorn D; Moore A; Sarfaty M; Yerushalmi R; Goldvaser H
Cancer Med; 2020 Jul; 9(13):4603-4612. PubMed ID: 32372569
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling in breast cancer: a clinical perspective.
Arpino G; Generali D; Sapino A; Del Matro L; Frassoldati A; de Laurentis M; Pronzato P; Mustacchi G; Cazzaniga M; De Placido S; Conte P; Cappelletti M; Zanoni V; Antonelli A; Martinotti M; Puglisi F; Berruti A; Bottini A; Dogliotti L
Breast; 2013 Apr; 22(2):109-120. PubMed ID: 23462680
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
14. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
15. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract][Full Text] [Related]
16. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
17. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.
Pérez Ramírez S; Del Monte-Millán M; López-Tarruella S; Martínez Jáñez N; Márquez-Rodas I; Lobo Samper F; Izarzugaza Perón Y; Rubio Terres C; Rubio Rodríguez D; García-Sáenz JÁ; Moreno Antón F; Zamora Auñón P; Arroyo Yustos M; Lara Álvarez MÁ; Ciruelos Gil EM; Manso Sánchez L; Echarri González MJ; Guerra Martínez JA; Jara Sánchez C; Bueno Muiño C; García Adrián S; Carrión Galindo JR; Valentín Maganto V; Martín M
Clin Transl Oncol; 2020 May; 22(5):717-724. PubMed ID: 31300934
[TBL] [Abstract][Full Text] [Related]
18. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
19. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract][Full Text] [Related]
20. European inter-institutional impact study of MammaPrint.
Cusumano PG; Generali D; Ciruelos E; Manso L; Ghanem I; Lifrange E; Jerusalem G; Klaase J; de Snoo F; Stork-Sloots L; Dekker-Vroling L; Lutke Holzik M
Breast; 2014 Aug; 23(4):423-8. PubMed ID: 24685596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
